2022 Global Conference Coverage: An Update on the Clinical Developments Across Gynecologic Malignancies *

2022; SGO, March; ASCO, June, ESMO, September; IGCS September; ESGO, October
Get up to date on emerging data in cervical, endometrial, and ovarian cancers presented at the 2022 meetings of SGO, ASCO, ESMO, IGCS, and ESGO with expert podcasts, commentaries, downloadable slides, and a “year in review” module.

Share

Program Content

Activities

Gyn 2022 Highlights
CCO 2022 Global Conference Coverage: Gynecologic Cancer Updates
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 10, 2022

Expires: November 09, 2023

View Activity

Activities

SGO 2022: GynOnc
Expert Insight on Key Data From SGO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2022

Expires: May 18, 2023

View Activity
ASCO 2022: GynOnc
Expert Insights on New Data From ASCO 2022 Informing Treatment for Endometrial, Ovarian, and Cervical Cancers
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: June 30, 2022

Expires: June 29, 2023

View Activity
ESMO 2022: OC Updates
Expert Insights on Key Updates From the 2022 ESMO Congress on PARP Inhibitors in Ovarian Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 04, 2022

Expires: October 03, 2023

View Activity
IGCS 2022
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 24, 2022

Expires: October 23, 2023

View Activity
ESGO 2022
Expert Thoughts on Studies of Interest Presented at the 2022 ESGO Annual Meeting on Gynecologic Cancers
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 30, 2022

Expires: November 29, 2023

View Activity

Activities

FAQs: Novel Tx GynOnc
FAQs: Integrating Novel Therapies Into the Management of Gynecologic Cancers
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2022

Expires: May 22, 2023

View Activity
GynOnc: Sequencing Therapy
Selecting and Sequencing New Treatment Strategies in Gynecologic Cancers
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: July 05, 2022

Expires: July 04, 2023

View Activity
Ovarian Cancer: ESMO Updates
Practical Considerations for Using PARP Inhibitors in Ovarian Cancer: Key ESMO Congress Updates
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 19, 2022

Expires: October 18, 2023

View Activity
IGCS 2022: Cervical, Ovarian
Key Updates in Cervical and Ovarian Cancers: IGCS 2022 Annual Meeting
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2022

Expires: November 02, 2023

View Activity
2022 ESGO: Key Data
2022 ESGO Congress: Experts Discuss HRD Testing, PARP Inhibitors in Recurrent Ovarian Cancer, and QoL in Nonepithelial Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: December 02, 2022

Expires: December 01, 2023

View Activity

Activities

Gyn Conferences 2022
Expert Analyses of Key Clinical Developments and Updates Across Gynecologic Malignancies
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 23, 2023

Expires: January 22, 2024

View Activity

Faculty

cover img faculity

Susana Banerjee, MBBS, MA, PhD, FRCP

Consultant Medical Oncologist
Research Lead,
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom

cover img faculity

Jubilee Brown, MD

Professor and Division Director
Gynecologic Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

cover img faculity

Elisabeth Diver, MD

Clinical Assistant Professor
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Stanford University
Stanford Cancer Institute
Stanford University Hospital and Clinics
Stanford, California

cover img faculity

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

cover img faculity

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

cover img faculity

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

cover img faculity

David Scott Miller, MD, FACOG, FACS

Professor of Obstetrics & Gynecology
Dallas Foundation Chair in Gynecologic Oncology
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Parkland Health & Hospital System
Dallas, Texas

cover img faculity

Mansoor Raza Mirza, MD

Medical Director
Department of Oncology
Chief Oncologist
The Finsen Centre
Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

cover img faculity

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

cover img faculity

Angeles Alvarez Secord, MD, MHSc

Professor
Division of Gynecologic Oncology
Department of OB/GYN
Duke Cancer Institute
Duke University Health System
Durham, North Carolina

cover img faculity

Ignace Vergote, MD, PhD

Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Karyopharm Therapeutics Inc.

Merck Sharp & Dohme Corp.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.